Therapeutics based on antibodies (Abs) are at the forefront of revolutionary treatments for cancer, autoimmunity and many other diseases. The application of high-throughput sequencing (HTS) in monoclonal Ab (mAb) screening and selection are rapidly transforming the discovery process. Nestor Bernat, Josine Lohuis and Henk-Jan at ENPICOM discuss the impact of HTS and immuno-informatics on the accuracy and speed of Ab discovery workflows, and how these technologies are revolutionising the Ab development field.